Swiss National Bank Has $323.94 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Swiss National Bank decreased its position in Bristol-Myers Squibb (NYSE:BMY) by 4.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,727,400 shares of the biopharmaceutical company’s stock after selling 289,300 shares during the quarter. Swiss National Bank owned 0.28% of Bristol-Myers Squibb worth $323,942,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. raised its position in Bristol-Myers Squibb by 169.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 186,395 shares of the biopharmaceutical company’s stock valued at $10,543,000 after buying an additional 117,224 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of Bristol-Myers Squibb by 70.2% during the 4th quarter. Rakuten Securities Inc. now owns 1,166 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 481 shares in the last quarter. Avantax Advisory Services Inc. raised its holdings in shares of Bristol-Myers Squibb by 18.1% in the fourth quarter. Avantax Advisory Services Inc. now owns 218,223 shares of the biopharmaceutical company’s stock valued at $12,343,000 after purchasing an additional 33,423 shares during the last quarter. Essential Planning LLC. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $384,000. Finally, Truvestments Capital LLC boosted its holdings in Bristol-Myers Squibb by 9.3% during the fourth quarter. Truvestments Capital LLC now owns 6,802 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 581 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on BMY shares. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Truist Financial upped their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price target for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Citigroup upped their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Finally, Cantor Fitzgerald increased their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $57.86.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $59.83 on Thursday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The stock has a market cap of $121.40 billion, a PE ratio of -13.54, a P/E/G ratio of 2.07 and a beta of 0.43. The firm has a 50-day moving average of $57.69 and a 200-day moving average of $55.41. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 4.15%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s payout ratio is -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.